Starting Four Kidney-Protective Diabetes Drugs Together
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether starting four blood-pressure and kidney-protective medications at the same time is safe and effective for people with type 2 diabetes and early kidney disease. The goal is to slow kidney damage and reduce heart and kidney problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–84 years
- Type 2 diabetes (not type 1)
- Kidney function between 45–90 mL/min/1.73 m² (mild to moderate kidney disease)
- High protein in urine (>200 mg/g, a sign of kidney stress)
- Currently taking 2 or fewer of the study medications for at least 4 weeks
- Healthy liver function and potassium levels; not pregnant or planning pregnancy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medicine called finerenone can protect kidney function in people with type 2 diabetes and early-to-moderate chronic kidney disease. It may be an option if you are already on blood pressure medication and have some protein in your urine.
This study tests if a combination drug (sacubitril/valsartan) can help control blood pressure and protect the kidneys in people with both high blood pressure and type 2 diabetes who have early signs of kidney damage.
This Phase 3 trial tests whether starting a diabetes medicine called dapagliflozin can better slow kidney damage than starting metformin in adults with type 2 diabetes. It may help preserve kidney function over time and reduce future kidney decline.
This study tests a four-drug combination to see if it can better protect the kidneys in people with type 2 diabetes and kidney disease. If you qualify, you may receive this combination therapy and be monitored for 6 months.
This trial tests whether combining dapagliflozin (a water-pill-like diabetes drug) with finerenone (a kidney-protective medication) works better than dapagliflozin alone for people with type 2 diabetes and kidney damage. Both drugs help reduce protein in urine and may slow kidney disease progression.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.